Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis

Bai, Yu, Hu, Yunxia, Zhao, Yanhua, Yu, Xizhong, Xu, Junwei, Hua, Zhiyun, Zhao, Zhiqiang · 2017 · Supportive Care in Cancer

Abstract

Purpose The aim of this study was to evaluate the therapeutic effects of Anamorelin on patients with cancer anorexia-cachexia syndrome (CACS) based on a meta-analysis of published randomized trials.Methods We searched PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases. Data from each selected study were evaluated individually. All continuous outcomes were calculated by the mean difference or standardized mean difference with 95% confidence interval for each study. Heterogeneity was assessed by using the Chi 2 test at a significance level of P < 0.1, in addition to the I 2 statistic (I 2 > 50% indicated substantial heterogeneity).Result At last, four studies were included from 284 records. In three studies, lean body mass was reported and there was a significant difference between placebo and Anamorelin groups (P < 0.00001), without significant heterogeneity (I 2 = 0%). All the four studies reported the body weight change from baseline, and there was significant difference between placebo and Anamorelin groups (P = 0.007), but with high heterogeneity (I 2 = 97%). Two studies reported Anderson Symptom Assessment Scale (ASAS) score, and Anamorelin significantly increased the total ASAS score of CACS patients (P < 0.00001), without any heterogeneity (I 2 = 0%). Three studies reported non-dominant handgrip strength, and there was no significant difference between Anamorelin and placebo groups (P = 0.16). Three studies reported insulin-like growth factor-1 level, and there was significant difference between Anamorelin and placebo groups (P = 0.02), but with high heterogeneity (I 2 = 96%). Three studies reported IGF binding protein-3 concentration. Anamorelin significantly increased such concentration compared with placebo did (P < 0.00001). However, there was still higher heterogeneity (I 2 = 59%). All the included studies reported adverse events. Compared with placebo, Anamorelin induced fewer adverse events, but there was no significant difference between the two groups (RR = 0.07, P = 0.35).Conclusion In the included studies, Anamorelin had some positive effects to relieve the symptoms and improved the quality of life. However, the heterogeneity was apparent, so the clinical effects of Anamorelin should be further validated by increasing the sample size, varying the range of doses during treatment, and observing other outcomes. We are still confident for the future application of Anamorelin in phase III clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00520-016-3560-0

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88:2164–2171 · doi:10.1002/(sici)1097-0142(20000501)88:9<2164::aid-cncr24>3.0.co;2-5

Cited by

See all 52

Metadata

Authors
Bai, Y., Hu, Y., Zhao, Y., Yu, X., Xu, J., Hua, Z., & Zhao, Z.
Affiliations
Nanjing University of Chinese Medicine (CN)
Corresponding author
Zhao, Zhiqiang
Venue
Supportive Care in Cancer
Published
2017-01-10
Volume
25
Issue
5
Pages
1651-1659
ISSN
  • 0941-4355 (ISSN-L)
  • 1433-7339
OpenAlex
W2569392536
Cited by
52
References
32
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 10 · 2017: 8
FWCI
1.04
Type
journal article
Language
en
Open access
closed
Locations
  • Supportive Care in Cancer (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81373608)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords
cancer anorexia-cachexia syndrome, lean body mass, body weight, grip strength, insulin-like growth factor I, IGF binding protein-3, adverse events, quality of life, growth hormone secretagogues, placebo comparison, heterogeneity of results, quality of evidence
MeSH terms
Anorexia, Cachexia, Female, Humans, Hydrazines, Neoplasms, Oligopeptides, Quality of Life, Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s00520-016-3560-0
The paper
Bai, Y., Hu, Y., Zhao, Y., Yu, X., Xu, J., Hua, Z., & Zhao, Z. (2017). Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Supportive Care in Cancer. https://doi.org/10.1007/s00520-016-3560-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.